Our proprietary in vitro discovery and engineering platform enables us rapidly screen billions of variants and isolate the ones with the best properties and lowest liability.
Our dedicated R&D team is engaged in developing a wide range of biologics modalities, including monoclonal and bispecific antibodies, nanobodies, and short peptides, all customized to meet your specific requirements.
We enthusiastically invite potential partners to get in touch with us regarding licensing our cutting-edge technologies and platform.